A share price of Climb Bio Inc [CLYM] is currently trading at $1.88, down -6.00%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLYM shares have gain 13.94% over the last week, with a monthly amount drifted -7.84%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Climb Bio Inc [NASDAQ: CLYM] stock has seen the most recent analyst activity on October 13, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $9. Previously, Robert W. Baird started tracking the stock with Outperform rating on August 15, 2025, and set its price target to $9. On June 06, 2025, Oppenheimer initiated with a Outperform rating and assigned a price target of $10 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $7 on May 22, 2025. Leerink Partners initiated its recommendation with a Outperform and recommended $10 as its price target on December 02, 2024.
Climb Bio Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $5.47. Climb Bio Inc [NASDAQ: CLYM] shares were valued at $1.88 at the most recent close of the market.
Analyzing the CLYM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.23 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Climb Bio Inc [NASDAQ:CLYM] is 14.08. In addition, the Quick Ratio stands at 14.08 and the Cash Ratio stands at 3.66.
Transactions by insiders
Recent insider trading involved Brennan Aoife, President and CEO, that happened on Jun 30 ’25 when 20618.0 shares were sold. SVP, Finance & CAO, Pimblett Emily completed a deal on Jun 20 ’25 to sell 1242.0 shares. Meanwhile, SVP, Finance & CAO Pimblett Emily sold 1199.0 shares on Mar 20 ’25.
